<p><b>OBJECTIVE</b>To evaluate the
efficacy and
safety of adefovir dipivoxil in
treatment of decompensated
liver cirrhosis patients with YMDD motif
mutation during
lamivudine therapy.</p><p><b>
METHODS</b>The
disease relapsed in 14
hepatitis B patients with decompensated
liver cirrhosis during
lamivudine treatment due to the YMDD motif
mutation. All 14
patients had positive HVBDNA and active
hepatitis, and were evaluated as
Child-Pugh Score C (CPS-C). The
patients were treated with
lamivudine 50 mg/d and adefovir dipivoxil 10 mg/d for 6 months.</p><p><b>RESULTS</b>One
patient signed off due to non-hypoxemic hyperlactacidemia; other 13
patients showed decreased
serum HBVDNA. All
patients had
serum HBVDNA < or =10(5) copies/ml and 7
patients had HBVDNA < or =10(4) copies/ml. Six
patients regained normal
serum ALT level and
Child-Pugh scores decreased in all
patients.</p><p><b>CONCLUSION</b>Adefovir dipivoxil has satisfied
efficacy and
safety in
treatment of decompensated
liver cirrhosis patients with YMDD motif
mutation during
lamivudine treatment.</p>